´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.

TransIT¢ç-Oligo Transfection Reagent

-

Á¦Á¶»ç Á¦Ç°ÄÚµå Á¦Ç°¸í ¿ë·® °¡°Ý
(ºÎ°¡¼¼º°µµ)
ºñ°í »ç¿ëÀڸŴº¾ó
Mirus
MIR 2164
TransIT-Oligo Transfection Reagent
°ü·ÃÇмú ±¸¸ÅÇϱâ
0.4 ml
°¡°Ý¹®ÀÇ   ml016_transit_oligo.pdf
Mirus
MIR 2160
TransIT-Oligo Transfection Reagent
°ü·ÃÇмú ±¸¸ÅÇϱâ
1 ml
°¡°Ý¹®ÀÇ  
Mirus
MIR 2165
TransIT-Oligo Transfection Reagent
°ü·ÃÇмú ±¸¸ÅÇϱâ
1 ml¡¿5
°¡°Ý¹®ÀÇ  
Mirus
MIR 2166
TransIT-Oligo Transfection Reagent
°ü·ÃÇмú ±¸¸ÅÇϱâ
1 ml¡¿10
°¡°Ý¹®ÀÇ  

  • Unique Formulation - Maximize transfection performance of oligonucleotides into a wide range of cells.
  • Low Cellular Toxicity - Maintain cell density and reduce experimental biases.
  • High Efficiency Delivery - Achieve high transfection efficiency in cells to ensure experimental success.


Figure 1. The TransIT-Oligo Reagent Achieves High Transfection Efficiency. HeLa cells transfected using TransIT-Oligo Reagent and Label IT Cy™3 and Label IT Fluorescein labeled phosphothioate DNA oligos in complete media for 24 hours.



Figure 2. The TransIT-Oligo Reagent Effectively Transfects a 2'OMe RNA Oligo that Blocks a Cryptic Splice Site. The HeLa-Luc 705 reporter cell line (Kang et al. 1998, 37:6235) used in this study contains a luciferase reporter construct that has the ©¬-globin 705 intron inserted into the luciferase ORF. A mutation present at position 705 of the ©¬-globin intron activates two cryptic splice sites within the intron that lead to the production of a spliced luciferase mRNA that is disrupted by a small intron with an in-frame stop codon, thus preventing translation of functional luciferase protein. The transfection of a 2'OMe oligonucleotide complementary to the cryptic 705 splice site inhibits splicing at the cryptic splice sites enabling the complete removal of the ©¬-globin intron and production of a mRNA with a complete, uninterrupted luciferase ORF.

The HeLa-Luc 705 cell line was transfected with increasing amounts of the anti-705 splice site 2'OMe RNA oligo at the indicated final concentrations using the TransIT-Oligo Transfection Reagent. The cells were harvested 24 hours post-transfection and assayed for luciferase activity. The increase in luciferase activity indicates effective delivery of the anti-705 splice site RNA oligo using the TransIT-Oligo Reagent.

Keyword : V2160,MIR2160,V2164,MIR2164,V2165T,MIR2165,V2166,MIR2166

µµÀÔ¹°Áú¿¡ µû¸¥ µµÀԽþà
>
Large RNA & CRISPR guide RNA¿ëtransfection ..
TransIT¢ç-mRNA Transfection Kit
>
mRNA, sgRNA, siRNAµî ´Ù¾çÇÑ RNA transfection..
Xfect¢â RNA Transfection Reagent